Agios on today’s phase 2 data for the pyruvate kinase activator mitapivat in sickle cell disease
Brian Goff, CEO of Agios Pharma, on today's phase 2 SCD data and how he thinks maitapivat can fit into the competitive landscape.
top of page
Follow BiotechTV
Also look for unique social pages for BiotechTV U.
.png){kind=logo}
Popular
#1. Ultragenyx's Emil Kakkis on Angelman syndrome data, rare disease treatment modalities, and more
#2. The CEO of Madrigal on the launch of Rezdiffra for NASH liver disease
#3. Sutro Biopharma's CEO on ADCs, non-cell protein synthesis, and more
#4. Verve Therapeutics' CEO on today's gene editing clinical trial pause
#5. Daphne Zohar on becoming the CEO of Seaport Therapeutics and a $100M series A
bottom of page